Cellular and molecular immunology of lung cancer: therapeutic implications

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Moolgavkar SH, Holford TR, Levy DT, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst 2012;104:541-8
   PubMedGoogle Scholar
• American Cancer Society. Cancer facts and figures 2014. Atlanta: American Cancer Society; 2014
   Google Scholar
• Hirsch FR, Franklin WA, Gazdar AF, Bunn PA. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001;7:5-22
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011;331:1565-70
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306:1891-901
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-15
   PubMed Web of Science ®Google Scholar
• O’Callaghan D, O’Donnell D, O’Connell F, O’Byrne K. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 2010;5:2024-36
   PubMed Web of Science ®Google Scholar
• Tan T-T, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007;19:209-16
   PubMed Web of Science ®Google Scholar
• Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 2014;00:1-9
   Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15
   PubMed Web of Science ®Google Scholar
• Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manage Res 2014;6:63-75
   PubMed Web of Science ®Google Scholar
• Kelly R, Giaccone G. Lung cancer - vaccines. Cancer J 2011;17:302-8
   PubMed Web of Science ®Google Scholar
• Yano T, Haro A, Shikada Y, et al. Non-small cell lung cancer in never smokers as a representative “non-smoking-associated lung cancer”: epidemiology and clinical features. Int J Clin Oncol 2011;16:287-93
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94
   PubMed Web of Science ®Google Scholar
• Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med 2011;32:703-40
   PubMed Web of Science ®Google Scholar
• Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer 2012;131:2724-32
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. volume 83: World Health Organization International Agency for Research on Cancer. Lyon, France: 2004
   Google Scholar
• Takahashi H, Ogata H, Nishigaki R, et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010;17:89-97
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44
   PubMed Web of Science ®Google Scholar
• Beane J, Vick J, Schembri F, et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev Res 2011;4:803-17
   PubMed Web of Science ®Google Scholar
• DeMarini DM. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat Res 2004;567:447-74
   PubMed Web of Science ®Google Scholar
• Ogino S, Galon J, Fuchs C, Dranoff G. Cancer immunology - analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8:617-32
   Web of Science ®Google Scholar
• Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002;21:7435-51
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80
   PubMed Web of Science ®Google Scholar
• Wan YY, Flavell RA. How diverse–CD4 effector T cells and their functions. J Mol Cell Biol 2009;1:20-36
   PubMed Web of Science ®Google Scholar
• Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 2010;238:247-62
   PubMed Web of Science ®Google Scholar
• Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2012;28:445-89
   Web of Science ®Google Scholar
• Ito N, Suzuki Y, Taniguchi Y, et al. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 2005;25:2027-31
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-7
   PubMed Web of Science ®Google Scholar
• Wilke CM, Kryczek I, Wei S, et al. Th17 cells in cancer: help or hindrance? Carcinogenesis 2011;32:643-9
   PubMed Web of Science ®Google Scholar
• Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10:248-56
   PubMed Web of Science ®Google Scholar
• Chang SH, Mirabolfathinejad SG, Katta H, et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci USA 2014;111:5664-9
   PubMed Web of Science ®Google Scholar
• Shimizu K, Nakata M, Hirami Y, et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5:585-90
   PubMed Web of Science ®Google Scholar
• Duan M-C, Zhong X-N, Liu G-N, Wei J-R. The Treg/Th17 Paradigm in Lung Cancer. J Immunol Res 2014;2014:1-9
   Web of Science ®Google Scholar
• Braumüller H, Wieder T, Brenner E, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494:361-5
   PubMed Web of Science ®Google Scholar
• Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-7
   PubMed Web of Science ®Google Scholar
• Haabeth OAW, Lorvik KB, Hammarström C, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011;2:240
   PubMed Web of Science ®Google Scholar
• Calzascia T, Pellegrini M, Hall H, et al. TNF- α is critical for antitumor but not antiviral T cell immunity in mice. J Clin Investig 2007;117:3833-45
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94:275-80
   PubMed Web of Science ®Google Scholar
• Neurath MF, Finotto S. The emerging role of T cell cytokines in non-small cell lung cancer. Cytokine Growth Factor Rev 2012;23:315-22
   PubMed Web of Science ®Google Scholar
• Gocheva V, Wang H-W, Gadea BB, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010;24:241-55
   PubMed Web of Science ®Google Scholar
• Li X, Shi W, Yu G, et al. Interleukin-4 -590T/C polymorphism influences the susceptibility to nonsmall cell lung cancer. DNA Cell Biol 2012;31:797-800
   PubMed Web of Science ®Google Scholar
• Ochoa CE, Mirabolfathinejad SG, Ruiz VA, et al. Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res 2011;4:51-64
   PubMed Web of Science ®Google Scholar
• Hagenbaugh A, Sharma S, Dubinett SM, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997;185:2101-10
   PubMed Web of Science ®Google Scholar
• Sharma S, Stolina M, Lin Y, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999;163:5020-8
   PubMed Web of Science ®Google Scholar
• Hatanaka H, Abe Y, Kamiya T, et al. Clinical implications of interleukin (IL) -IO induced by non-small-cell lung cancer. Ann Oncol 2000;815-19
   PubMed Web of Science ®Google Scholar
• Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004;53:79-85
   PubMed Web of Science ®Google Scholar
• De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Dieu-Nosjean M-C, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093-102
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71
   PubMed Web of Science ®Google Scholar
• Zhang JY, Green CL, Tao S, Khavari PA. NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes Dev 2004;18:17-22
   PubMed Web of Science ®Google Scholar
• Sethi G, Sung B, Aggarwal BB. TNF: A master switch for inflammation to cancer. Front Biosci 2008;5094-107
   PubMed Web of Science ®Google Scholar
• Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, et al. VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer 2009;64:219-25
   PubMed Web of Science ®Google Scholar
• Boldrini L, Calcinai A, Samaritani E, et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer 2000;83:480-6
   PubMed Web of Science ®Google Scholar
• Ohri CM, Shikotra A, Green RH, et al. Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer 2010;10:323
   PubMed Web of Science ®Google Scholar
• Colakogullari M, Ulukaya E, Oral AY, et al. The involvement of IL-10, IL-6, IFN- g, TNF- a and TGF- b gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct 2008;26:283-90
   PubMed Web of Science ®Google Scholar
• Shih C-M, Lee Y-L, Chiou H-L, et al. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 2006;52:15-20
   PubMed Web of Science ®Google Scholar
• Brown DM. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol 2010;262:89-95
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9
   PubMed Web of Science ®Google Scholar
• Vaccine therapy in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer. Available from: http://clinicaltrials.gov/show/NCT00104780
   Google Scholar
• Barve M, Bender J, Senzer N, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008;26:4418-25
   PubMed Web of Science ®Google Scholar
• PR Newswire. Agreement on Phase 3 Trial Protocol of OSE Pharma’s OSE-2101 from the FDA and EMA. 2014
   Google Scholar
• Wilke CM, Bishop K, Fox D, Zou W. Deciphering the role of Th17 cells in human disease. Trends Immunol 2011;32:603-11
   PubMed Web of Science ®Google Scholar
• Middleton GW, Annels NE, Pandha HS. Are we ready to start studies of Th17 cell manipulation as a therapy for cancer? Cancer Immunol Immunother 2012;61:1-7
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-9
   PubMed Web of Science ®Google Scholar
• Ye Z-J, Zhou Q, Gu Y-Y, et al. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol 2010;185:6348-54
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64
   PubMed Web of Science ®Google Scholar
• Lin W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83
   PubMed Web of Science ®Google Scholar
• Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005;175:6177-89
   PubMed Web of Science ®Google Scholar
• Li Q, Han Y, Fei G, et al. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett 2012;148:144-50
   PubMed Web of Science ®Google Scholar
• Chen X, Wan J, Liu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010;69:348-54
   PubMed Web of Science ®Google Scholar
• Gu Y, Yang J, Ouyang X, et al. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol 2008;38:1807-13
   PubMed Web of Science ®Google Scholar
• Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009;31:787-98
   PubMed Web of Science ®Google Scholar
• Ersvær E, Melve GK, Bruserud O. Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation? Cancer Immunol Immunother 2011;60:1669-81
   PubMed Web of Science ®Google Scholar
• Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 2013;73:2381-8
   PubMed Web of Science ®Google Scholar
• Sharma S, Yang S, Zhu L, et al. Tumor cyclooxygenase-2/ prostaglandin E 2 − dependent promotion of FOXP3 expression and CD4 + CD25 + T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-20
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-11
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Takanashi S, Kanehira Y, et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001;91:964-71
   PubMed Web of Science ®Google Scholar
• Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003;100:8621-3
   PubMed Web of Science ®Google Scholar
• Li S, Li Y, Qu X, et al. Detection and significance of TregFoxP3+ and Th17 cells in peripheral blood of non-small cell lung cancer patients. Arch Med Sci 2014;2:232-9
   Google Scholar
• Tao H, Mimura Y, Aoe K, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 2012;75:95-101
   PubMed Web of Science ®Google Scholar
• Wang K, Grivennikov SI, Karin M. Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases. Ann Rheum Dis 2013;72(Suppl 2):ii100-3
   Google Scholar
• Li X, Kostareli E, Suffner J, et al. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol 2010;40:3325-35
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013;73:539-49
   PubMed Web of Science ®Google Scholar
• Ali K, Soond DR, Piñeiro R, et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014;510(7505):407-11
   PubMed Web of Science ®Google Scholar
• Li J-Y, Duan X-F, Wang L-P, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res 2014;2014:286170
   PubMed Web of Science ®Google Scholar
• Alistair C, Alison M, Bruce R, et al. Optimising regulatory T cell (Treg) depletion in combination with chemotherapy for enhanced anti-tumour immunity. Front Immunol 2013. 4: Conference abstract presented August 2013
   Google Scholar
• Gitlitz BJ, Bernstein E, Santos ES, et al. A randomized, placebo-controlled, multicenter, biomarker-selected, Phase 2 study of apricoxib in combination with erlotinib in patients with advanced non–small-cell lung cancer. J Thorac Oncol 2014;9:577-82
   PubMed Web of Science ®Google Scholar
• Schneberger D, Aharonson-Raz K, Singh B. Monocyte and macrophage heterogeneity and Toll-like receptors in the lung. Cell Tissue Res 2011;343:97-106
   PubMed Web of Science ®Google Scholar
• Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008;267:204-15
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7
   PubMed Web of Science ®Google Scholar
• Ma J, Liu L, Che G, et al. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010;10:112
   PubMed Web of Science ®Google Scholar
• Standiford TJ, Kuick R, Bhan U, et al. TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 2011;30:2475-84
   PubMed Web of Science ®Google Scholar
• Porta C, Rimoldi M, Raes G, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci USA 2009;106:14978-83
   PubMed Web of Science ®Google Scholar
• Hagemann T, Lawrence T, McNeish I, et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008;205:1261-8
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12
   PubMed Web of Science ®Google Scholar
• Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation. Cell 2003;112:645-57
   PubMed Web of Science ®Google Scholar
• Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99:1441-54
   PubMed Web of Science ®Google Scholar
• Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009;13:2780-6
   PubMed Web of Science ®Google Scholar
• Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009;86:1065-73
   PubMed Web of Science ®Google Scholar
• Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011;9:216
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-16
   PubMed Web of Science ®Google Scholar
• Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-67
   PubMed Web of Science ®Google Scholar
• Dai F, Liu L, Che G, et al. The number and microlocalization of tumor-associated immune cells are associated with patient’s survival time in non-small cell lung cancer. BMC Cancer 2010;10:220
   PubMed Web of Science ®Google Scholar
• Germain C, Gnjatic S, Tamzalit F, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014;189:832-44
   PubMed Web of Science ®Google Scholar
• Perrot I, Blanchard D, Freymond N, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007;178:2763-9
   PubMed Web of Science ®Google Scholar
• Dumitriu IE, Dunbar DR, Howie SE, et al. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2009;182:2795-807
   PubMed Web of Science ®Google Scholar
• Chiba S, Baghdadi M, Akiba H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012;13:832-42
   PubMed Web of Science ®Google Scholar
• Curiel T, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell – mediated antitumor immunity. Nat Med 2003;9:5-10
   Web of Science ®Google Scholar
• Viaud S, Théry C, Ploix S, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what’s next? Cancer Res 2010;70:1281-5
   PubMed Web of Science ®Google Scholar
• Trial of a vaccination with tumor antigen-loaded dendritic cell-derived exosomes (CSET 1437). Available from: http://clinicaltrials.gov/show/NCT01159288
   Google Scholar
• Shi S-B, Tang X-Y, Tian J, et al. Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. J Immunother 2014;37:250-5
   PubMed Web of Science ®Google Scholar
• Chen R, Deng X, Wu H, et al. Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis. Int Immunopharmacol 2014;22:451-64
   PubMed Web of Science ®Google Scholar
• Soliman HH, Minton SE, Han HS, et al. A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. J Clin Oncol 2014;31(Suppl):abstract 30609
   Google Scholar
• Vaccine therapy and 1-MT in treating patients with metastatic breast cancer. Available from: http://clinicaltrials.gov/show/NCT01042535
   Google Scholar
• Vivier E, Ugolini S, Blaise D, et al. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012;12:239-52
   PubMed Web of Science ®Google Scholar
• Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology 2009;128:151-63
   PubMed Web of Science ®Google Scholar
• Platonova S, Cherfils-Vicini J, Damotte D, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011;71:5412-22
   PubMed Web of Science ®Google Scholar
• Hodge G, Barnawi J, Jurisevic C, et al. Lung cancer is associated with decreased expression of perforin, granzyme B and IFNγ by infiltrating lung tissue T cells, NKT-like and NK cells. Clin Exp Immunol 2014;178(1):79-85
   Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 2008;112:863-75
   PubMed Web of Science ®Google Scholar
• Bruno A, Focaccetti C, Pagani A, et al. The proangiogenic phenotype of natural killer cells in patients with non – small cell lung cancer. Neoplasia 2013;15:133-42. IN7
   PubMed Web of Science ®Google Scholar
• Esendagli G, Bruderek K, Goldmann T, a, et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008;59:32-40
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006;214:229-38
   PubMed Web of Science ®Google Scholar
• Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009;266:154-81
   PubMed Web of Science ®Google Scholar
• Hiraki A, Kiura K, Yamane H, et al. Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer 2002;35:329-33
   PubMed Web of Science ®Google Scholar
• Krause SW, Gastpar R, Andreesen R, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 2004;10:3699-707
   PubMed Web of Science ®Google Scholar
• Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT). Available from: http://clinicaltrials.gov/show/NCT02118415
   Google Scholar
• Schneider T, Hoffmann H, Dienemann H, et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac 2011;6:1162-8
   PubMed Web of Science ®Google Scholar
• Bremnes RM, Sirera R, Al-saad S, et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis. J Thorac Oncol 2011;6:824-33
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang T, Ye J, et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012;61:1849-56
   PubMed Web of Science ®Google Scholar
• Wu R, Forget M, Chacon J, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012;18:160-75
   PubMed Web of Science ®Google Scholar
• Wang J, Wang X. Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer. Mol Biol Rep 2014;41:6317-23
   PubMed Web of Science ®Google Scholar
• Phase II/pilot study of 2nd generation anti-CEA designer T cells in adenocarcinomas. Available from: http://clinicaltrials.gov/show/NCT01723306
   Google Scholar
• Chemotherapy followed by ESO-1 lymphocytes and aldesleukin to treat metastatic cancer. Available from: http://clinicaltrials.gov/show/NCT00670748
   Google Scholar
• Treating cancer with anti-mesothelin modified lymphocytes. Available from: http://clinicaltrials.gov/show/NCT01583686
   Google Scholar
• Chmielewski M, Hombach A, Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 2013;4:371
   PubMed Web of Science ®Google Scholar
• Ozkaynak MF, Gilman AL, Yu AL, et al. A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM- CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children’s Oncology Group study. J Clin Oncol 2014;32(Suppl):abstract 10044
   Google Scholar
• De PF, Salazar R, Santos C, et al. A phase 1 mechanism of action study of intratumoral or intravenous administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumor. J Clin Oncol 2014;32(Suppl):abstract TPS3112
   Google Scholar
• Calvo E, Gil-martin M, Machiels JH, et al. A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors. J Clin Oncol 2014;32(Suppl):abstract 3103
   Google Scholar
• Hegde M, Wakefield A, Brawley VS, et al. Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance the control of high-grade glioma (HGG). J Clin Oncol 2014;32(Suppl):abstract 10027
   Google Scholar
• Moon EK, Wang L-C, Dolfi D V, et al. multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 2014;20:4262-73
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013;31:2396-403
   PubMed Web of Science ®Google Scholar
• GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small cell lung cancer. Available from: http://clinicaltrials.gov/show/NCT00480025
   Google Scholar
• Chustecka Z. MAGE A3 Vaccine now dropped for lung cancer. Medscape 2014
   Google Scholar
• Cuppens K, Vansteenkiste J. Vaccination therapy for non-small-cell lung cancer. Curr Opin Oncol 2014;26:165-70
   PubMed Web of Science ®Google Scholar
• Phase IIB/III Of TG4010 immunotherapy in patients with stage IV non-small cell lung cancer (TIME). Available from: http://clinicaltrials.gov/show/NCT01383148
   Google Scholar
• Quoix EA, Nemunaitis JJ, Burzykowski T, et al. TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30(Suppl):abstract TPS7610
   Google Scholar
• Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12:1125-33
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski M, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68
   PubMed Web of Science ®Google Scholar
• Cancer vaccine study for unresectable stage III non-small cell lung cancer (START). Available from: http://clinicaltrials.gov/show/NCT00409188
   Google Scholar
• Tecemotide following concurrent chemo-radiotherapy for non-small cell lung cancer (START2). Available from: http://clinicaltrials.gov/show/NCT02049151
   Google Scholar
• Cancer vaccine study for stage iii, unresectable, non-small cell lung cancer (NSCLC) in the Asian population (INSPIRE). Available from: http://clinicaltrials.gov/show/NCT01015443
   Google Scholar
• Wu Y-L, Park K, Soo R, et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011;11:430
   PubMed Web of Science ®Google Scholar
• Chustecka Z. Vaccine for lung cancer dropped from development. Medscape 2014
   Google Scholar
• Santiesteban E, Perez L, Alfonso S, et al. Safety and efficacy of racotumomab-alum vaccine as second-line therapy for advanced non-small cell lung cancer. IJCM 2014;5:844-50
   Google Scholar
• Alfonso S, Valdés-Zayas A, Santiesteban ER, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2014;20:3660-71
   PubMed Web of Science ®Google Scholar
• Immunotherapy with racotumomab in advanced lung cancer. Available from: http://clinicaltrials.gov/show/NCT01460472
   Google Scholar
• Phase III Lucanix™ vaccine therapy in advanced non-small cell lung cancer (NSCLC) following front-line chemotherapy (STOP). Available from: http://clinicaltrials.gov/show/NCT00676507
   Google Scholar
• Giaccone G, Bazhenova L, Nemunaitis J, et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small-cell lung cancer (NSCLC) [abstract LBA2]. European Cancer Congress; 2013. Presented 28 September 2013
   Google Scholar
• Postow M, Callahan M, Wolchok J. Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J 2011;17:372-8
   PubMed Web of Science ®Google Scholar
• A study of chemotherapy and ramucirumab versus (vs.) chemotherapy alone in second line non-small cell lung cancer participants who received prior first line platinum based chemotherapy. Available from: http://clinicaltrials.gov/show/NCT01168973
   Google Scholar
• Garon EB, Cao D, Alexandris E, et al. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale an. Clin Lung Cancer 2012;13:505-9
   PubMed Web of Science ®Google Scholar
• Perol M, Ciuleanu T-E, Arrieta O, et al. REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non- small cell lung cancer (NSCLC) following disease progression after one prior p. J Clin Oncol 2014;32(Suppl):abstract LBA8006
   Google Scholar
• LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/show/NCT00805194
   Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-55
   PubMed Web of Science ®Google Scholar
• Reck M, Mellemgaard A, Orlov S V, et al. Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D). J Clin Oncol 2014;32(Suppl):abstract 8100
   Google Scholar
• Lume lung 2 : BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC. Available from: http://clinicaltrials.gov/show/NCT00806819
   Google Scholar
• Hanna NH, Kaiser R, Sullivan RN, et al. Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013;31(Suppl):abstract 8034
   Google Scholar
• Ribas A, Kefford R, Marshall M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616-22
   PubMed Web of Science ®Google Scholar
• Hodi F, O’Day S, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-54
   PubMed Web of Science ®Google Scholar
• Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin. Available from: http://clinicaltrials.gov/show/NCT01285609
   Google Scholar
• Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012;13:e301-10
   PubMed Web of Science ®Google Scholar
• A phase 1b study of MDX-1106 in subjects with advanced or recurrent malignancies (MDX1106-03). Available from: http://clinicaltrials.gov/show/NCT00730639
   Google Scholar
• BMS-936558 (MDX-1106) In subjects with advanced/metastatic clear-cell renal cell carcinoma (RCC). Available from: http://clinicaltrials.gov/show/NCT01354431
   Google Scholar
• Phase I biomarker study (BMS-936558). Available from: http://clinicaltrials.gov/show/NCT01358721
   Google Scholar
• Study of nivolumab (BMS-936558) in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, carboplatin/paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB/IV non-small cell lung cancer (NSCLC) (CheckMate 012). Available from: http://clinicaltrials.gov/show/NCT01454102
   Google Scholar
• Antonia SJ, Gettinger SN, Quan L, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol 2014;1(Suppl):abstract 8023
   Google Scholar
• Ramlogan-Steel CA, Steel JC, Morris JC. Lung cancer vaccines: current status and future prospects. Transl Lung Cancer Res 2014;3:46-52
   PubMedGoogle Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006
   PubMed Web of Science ®Google Scholar
• Engelman J a, Jänne P a. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9
   PubMed Web of Science ®Google Scholar
• Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-6
   PubMed Web of Science ®Google Scholar